CO2019005247A2 - Composición farmacéutica para evitar la adicción a opioides - Google Patents

Composición farmacéutica para evitar la adicción a opioides

Info

Publication number
CO2019005247A2
CO2019005247A2 CONC2019/0005247A CO2019005247A CO2019005247A2 CO 2019005247 A2 CO2019005247 A2 CO 2019005247A2 CO 2019005247 A CO2019005247 A CO 2019005247A CO 2019005247 A2 CO2019005247 A2 CO 2019005247A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
patient
opioid addiction
prevent opioid
composition
Prior art date
Application number
CONC2019/0005247A
Other languages
English (en)
Spanish (es)
Inventor
John Davis
Catherine Stehman-Breen
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2019005247A2 publication Critical patent/CO2019005247A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CONC2019/0005247A 2016-11-29 2019-05-22 Composición farmacéutica para evitar la adicción a opioides CO2019005247A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29
PCT/US2017/063417 WO2018102294A1 (en) 2016-11-29 2017-11-28 A pharmaceutical composition for averting opioid addiction

Publications (1)

Publication Number Publication Date
CO2019005247A2 true CO2019005247A2 (es) 2019-05-31

Family

ID=60766150

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0005247A CO2019005247A2 (es) 2016-11-29 2019-05-22 Composición farmacéutica para evitar la adicción a opioides

Country Status (18)

Country Link
US (2) US10736961B2 (https=)
EP (1) EP3548082B1 (https=)
JP (1) JP7071975B2 (https=)
KR (1) KR20190090820A (https=)
CN (1) CN110072549A (https=)
AU (1) AU2017366870B2 (https=)
BR (1) BR112019010331A2 (https=)
CA (1) CA3045116A1 (https=)
CL (1) CL2019001385A1 (https=)
CO (1) CO2019005247A2 (https=)
EA (1) EA201991283A9 (https=)
IL (1) IL266640B (https=)
MA (2) MA45890B2 (https=)
MX (1) MX2019006013A (https=)
MY (1) MY200701A (https=)
PH (1) PH12019501087A1 (https=)
WO (1) WO2018102294A1 (https=)
ZA (1) ZA201902967B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210043624A (ko) 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
BRPI0815370B8 (pt) 2007-08-10 2021-05-25 Regeneron Pharma anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
BR112013008366B1 (pt) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações

Also Published As

Publication number Publication date
KR20190090820A (ko) 2019-08-02
MX2019006013A (es) 2019-10-14
BR112019010331A2 (pt) 2019-10-22
EP3548082B1 (en) 2024-05-15
AU2017366870B2 (en) 2024-09-19
AU2017366870A1 (en) 2019-06-06
MA45890B2 (fr) 2022-10-31
US10736961B2 (en) 2020-08-11
EP3548082A1 (en) 2019-10-09
MY200701A (en) 2024-01-11
CA3045116A1 (en) 2018-06-07
CN110072549A (zh) 2019-07-30
US20180147280A1 (en) 2018-05-31
US20210060159A1 (en) 2021-03-04
MA46951A (fr) 2019-10-09
EA201991283A9 (ru) 2019-11-27
MA45890A1 (fr) 2020-02-28
JP7071975B2 (ja) 2022-05-19
CL2019001385A1 (es) 2019-07-26
JP2019535716A (ja) 2019-12-12
US11491222B2 (en) 2022-11-08
IL266640B (en) 2022-09-01
PH12019501087A1 (en) 2019-08-19
ZA201902967B (en) 2024-10-30
IL266640A (en) 2019-07-31
WO2018102294A1 (en) 2018-06-07
EA201991283A1 (ru) 2019-09-30

Similar Documents

Publication Publication Date Title
DOP2023000187A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CO2019009586A2 (es) Anticuerpos anti-gitr y métodos de uso de los mismos
MX2021002322A (es) Nuevos metodos.
MX2023014921A (es) Anticuerpo anti-cd154 con caracteristicas de union, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana.
MX2020009862A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
MX2019009122A (es) ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
BR112018072681A8 (pt) Anticorpos anti-il-1r3 humanizados, fragmento ou derivado do mesmo, seu uso, combinação, e composição farmacêutica
CO2019005247A2 (es) Composición farmacéutica para evitar la adicción a opioides
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
NZ735777A (en) Methods and compositions to inhibit symptoms associated with veisalgia
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
CO6280488A2 (es) Combinacion farmaceutica
EA202190504A1 (ru) Способы лечения псориаза
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
CU20200015A7 (es) Composición farmacéutica y kit que comprenden anticuerpos anti-tnf alpha
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении
AU2020271352A8 (en) Combinations of anti-ILDR2 antibodies and PD-1 antagonists